• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Concert Pharmaceuticals

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · June 20, 2011

Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity

June 20 , 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform™ (deuterated chemical entity platform). CTP-499 is progressing into …

News · June 20, 2011

Concert Pharmaceuticals Announces Milestone Achievement in GlaxoSmithKline Collaboration

June 20 , 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone in its strategic alliance with GlaxoSmithKline (GSK) for its HIV protease inhibitor …

News · April 12, 2011

Concert Pharmaceuticals Expands Regulatory and Clinical Leadership with New Appointments

Mark Roessel Named Vice President of Regulatory Affairs and Quality Assurance LuAnn Sabounjian Named Vice President, Clinical Operations April 12 , 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. …

News · March 29, 2011

Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study

First-in-Class Drug Candidate from Deuterium Platform Has Anti-Inflammatory, Anti-Fibrotic, and Anti-Oxidant Properties March 29 , 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. today announced …

News · February 2, 2011

Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound

Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases and Injuries February 2, 2011 Lexington, MA -- Concert Pharmaceuticals, Inc. today announced that it has entered into a …

News · January 20, 2011

James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals

Additional Management Team Announcement with Promotion of Robert Silverman January 19, 2011, Lexington, MA -- Concert Pharmaceuticals, Inc. announced today the appointment of James E. Shipley, M.D., …

News · January 13, 2011

New Patents Continue to issue for Concert Pharmaceuticals Deuterium Chemistry Intellectual Property

January 13, 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. announced the issuance of several new patents relating to specific compounds derived from its DCE Platform™ (Deuterated Chemical Entity …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact